Datavault AI Inc (NASDAQ: DVLT), a provider of data monetisation, credentialing, digital engagement and real-world asset (RWA) tokenisation technologies, announced on Wednesday that it has signed a binding term sheet with health information technology to form DelivMeds AI, a healthcare platform integrating blockchain-enabled pharmacy infrastructure, biometric verification technology and AI-driven consumer health services.

The proposed venture, which is expected to carry an approximate combined asset value of USD4bn subject to an independent fairness opinion, will combine an expanded PharmacyChain licence, the acquisition of QOLPOM biometric health and drone logistics intellectual property, and a controlling stake in Tollo Health, LLC.

DelivMeds AI will connect to Wellgistics Health's network of more than 6,500 pharmacies and 200 manufacturers, using the company's EinsteinRx™ dispensing optimisation platform alongside Datavault AI's PharmacyChain smart contract infrastructure.

The QOLPOM intellectual property acquisition from EOS Technology Holdings, Inc and Scilex Holding Company (NASDAQ: SCLX) adds wearable-enabled biometric verification and drone-based pharmaceutical delivery capabilities designed to improve last-mile healthcare logistics and patient authentication, particularly in underserved rural markets.

The acquisition of a controlling interest in Tollo Health will add telemedicine, AI-enabled patient coaching and a portfolio of medical foods and supplements focused on GLP-1-related muscle loss, Long COVID and acute viral infections. The business also brings the "Health Lives Here" consumer health app, developed in partnership with NFL Alumni Health.

The companies plan to begin a pilot rollout of the Health Lives Here programme in North Carolina in July 2026 ahead of a broader launch linked to activities surrounding the 2026 Pro Football Hall of Fame Game in August.

Separately, Gerald Commissiong has been appointed interim co-chief executive of Wellgistics Health. The proposed transactions remain subject to due diligence, fairness opinions, definitive agreements, board approvals and customary closing conditions.